Eli Lilly seeking chronic kidney disease approval with Jardiance
The FDA has accepted an application from the US-based pharmaceutical company to expand the indication of diabetes drug Jardiance to include chronic kidney disease.
by ulrich quistgaard, translated by daniel pedersen
The US Food and Drug Administration (FDA) has received, and accepted, a supplemental new drug application from Eli Lilly that seeks to expand the indication of diabetes drug Jardiance to include chronic kidney disease (CDK).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly predicts possible launch of obesity drug in 2023
For subscribers
